published meta-analysis   sensitivity analysis   studies

corticosteroids in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCAPE-COVID, 2020 0.45 [0.20; 1.02] CODEX (Tomazini), 2020 0.97 [0.72; 1.31] Metcovid, 2020 0.92 [0.67; 1.28] RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92] REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45] REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53] 0.85[0.78; 0.94]CAPE-COVID, 2020, CODEX (Tomazini), 2020, Metcovid, 2020, RECOVERY dexamethasone, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 202060%7,764moderatenot evaluable clinical improvementdetailed resultsREMAP-CAP, fixed 7-day course, 2020 1.29 [0.82; 2.03] REMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64] 1.16[0.84; 1.60]REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 202020%498moderatenot evaluable clinical improvement (14-day)detailed resultsREMAP-CAP, fixed 7-day course, 2020 1.29 [0.82; 2.03] REMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64] 1.16[0.84; 1.60]REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 202020%498moderatenot evaluable clinical worseningdetailed resultsCODEX (Tomazini), 2020 0.66 [0.43; 1.02] 0.66[0.43; 1.02]CODEX (Tomazini), 202010%299moderatenot evaluable death or ventilationdetailed resultsCAPE-COVID, 2020 0.71 [0.37; 1.35] 0.71[0.37; 1.35]CAPE-COVID, 202010%149lownot evaluable hospital dischargedetailed resultsRECOVERY dexamethasone, 2020 1.10 [1.03; 1.17] 1.10[1.03; 1.17]RECOVERY dexamethasone, 202010%6,425moderatenot evaluable ventilationdetailed resultsCAPE-COVID, 2020 0.95 [0.44; 2.04] 0.95[0.44; 2.04]CAPE-COVID, 202010%149lownot evaluable superinfectiondetailed resultsCAPE-COVID, 2020 0.81 [0.49; 1.34] 0.81[0.49; 1.34]CAPE-COVID, 202010%149lownot evaluable serious adverse eventsdetailed resultsCODEX (Tomazini), 2020 0.53 [0.17; 1.62] REMAP-CAP, fixed 7-day course, 2020 3.01 [0.33; 27.32] REMAP-CAP, shock-dependent course, 2020 3.68 [0.42; 31.96] 1.35[0.34; 5.30]CODEX (Tomazini), 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020344%779moderatenot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2020-12-04 23:53 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 522,582,666,737,616,544,733 - roots T: 290